Bausch Health Companies (TSE:BHC) Stock Price Up 8.4% After Strong Earnings

Shares of Bausch Health Companies Inc. (TSE:BHCGet Free Report) traded up 8.4% during trading on Thursday following a better than expected earnings announcement. The company traded as high as C$12.37 and last traded at C$12.33. 36,968 shares changed hands during trading, a decline of 90% from the average session volume of 370,617 shares. The stock had previously closed at C$11.37.

The company reported C$1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$1.43 by C$0.10. The firm had revenue of C$3.42 billion during the quarter, compared to the consensus estimate of C$3.36 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BHC shares. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Raymond James upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 10th.

Read Our Latest Research Report on Bausch Health Companies

Insider Activity at Bausch Health Companies

In related news, Senior Officer Seana Lynne Carson sold 13,370 shares of Bausch Health Companies stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. 11.28% of the stock is currently owned by corporate insiders.

Bausch Health Companies Stock Up 9.1 %

The company has a market cap of C$4.55 billion, a PE ratio of -7.05, a PEG ratio of 0.21 and a beta of 0.77. The stock’s 50 day moving average price is C$9.82 and its 200-day moving average price is C$9.87. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

See Also

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.